Pipeline

Overview

Despite significant advances in oncology, there is still a large unmet need in treating patients with solid tumors, especially those with advanced disease. Our approach begins with our proprietary computational discovery platform to identify new drug targets and biological pathways that could enhance anti-cancer immune responses. With these new targets in hand and a deep understanding of their underlying biology, we are advancing new therapeutics and optimizing their combination to expand immuno-oncology treatment options to cancer patients who are not responsive to currently available drugs.

Pipeline PROGRAM TARGET PARTNER STAGE OF DEVELOPMENT Compugen-owned programs Partner programs *Dose escalation study Undisclosed AstraZeneca Bispecific Products Phase 1 Bayer BAY 1905254 + Keytruda® ILDR2, PD-1 Indication: Head & Neck Squamous Cell Carcinoma Phase 1 Bayer BAY 1905254* ILDR2 Indication: Advanced solid tumors Drug Discovery Myeloid Programs Undisclosed Phase 1 Indication: Advanced malignancies COM902 TIGIT Phase 1/2 Bristol Myers Squibb COM701 + Opdivo® + BMS-986207 PVRIG, PD-1, TIGIT Indication: Ovarian Cancer, Endometrial Cancer and high PVRL2-expressing tumors Indication: Advanced solid tumors Phase 1 Bristol Myers Squibb COM701 + Opdivo®* PVRIG, PD-1 Phase 1 Indication: NSCLC, Breast, Ovarian, Endometrial and Colorectal Cancer COM701 PVRIG A study of a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint computationally discovered by Compugen learn more » COM701 PVRIG A study of Compugen’s first-in-class PVRIG antibody, COM701, in combination with Opdivo® learn more » COM701 + Opdivo®* PVRIG, PD-1 A study evaluating the simultaneous triple blockade of PVRIG, PD-1 and TIGIT with Compugen’s first-in-class anti-PVRIG antibody... learn more » COM701 + Opdivo® + BMS-986207 PVRIG, PD-1, TIGIT A study of a therapeutic antibody COM902 against the immuno-oncology target TIGIT, a novel immune checkpoint... learn more » COM902 TIGIT Compugen’s computation drug target discovery platform has identified multiple potential myeloid targets and is pursuing the... learn more » Myeloid Programs Undisclosed ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally... learn more » BAY 1905254* ILDR2 ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally... learn more » BAY 1905254 + Keytruda® ILDR2, PD-1 Bispecific and multi-specific antibodies represent an emerging class of therapeutics learn more » Bispecific Products
Scroll to Top